Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
Cancer|September 19, 2002
Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimensSergio Ricci, Luca Galli, Aldo Chioni, et al.
Biomedical Reports|March 20, 2020
Clinical and economic effect of administration of red blood product transfusions in an outpatient supportive care cancer serviceAndrea Sbrana, Federico Paolieri, Francesco Bloise, et al.
Oncology Reports|July 29, 2003
Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapyCristina Granetto, Sergio Ricci, Andrea Martoni, et al.
Journal of Geriatric Oncology|November 2, 2019
Effectiveness of Multi-Prognostic Index in older patients with advanced malignancies treated with immunotherapyAndrea Sbrana, Rachele Antognoli, Giuseppe Pasqualetti, et al.
Targeted Oncology|May 20, 2016
Safety and QOL in Patients with Advanced NET in a Phase 3b Expanded Access Study of EverolimusMarianne Pavel, Nicole Unger, Ivan Borbath, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2005
Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancerHans von der Maase, Lisa Sengelov, James T Roberts, et al.
Gastrointestinal Cancer Research : GCR|June 16, 2011
Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B CirrhosisGhassan K Abou-Alfa, Dino Amadori, Armando Santoro, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2009
The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trialGiorgio V Scagliotti, Filippo De Marinis, Massimo Rinaldi, et al.
BMC Cancer|September 30, 2010
Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patientsIlaria Pastina, Elisa Giovannetti, Aldo Chioni, et al.
Nuclear Medicine Communications|October 26, 2013
Safety and antitumor efficacy of (153)Sm-EDTMP and docetaxel administered sequentially to patients with metastatic castration-resistant prostate cancerElisa Borsò, Giuseppe Boni, Ilaria Pastina, et al.
Pageof 5